BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37499745)

  • 1. Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA.
    Chen L; Ma R; Luo C; Xie Q; Ning X; Sun K; Meng F; Zhou M; Sun J
    Transl Res; 2023 Dec; 262():12-24. PubMed ID: 37499745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can circulating cell free DNA be a promising marker in ovarian cancer? - a genome-scale profiling study in a single institution.
    Zhou H; Zhang X; Liu Q; Yang J; Bai J; Yin M; Cao D; Zhang Q; Zheng L
    J Ovarian Res; 2023 Jan; 16(1):11. PubMed ID: 36641505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
    Wang Y; Zhou K; Wang X; Liu Y; Guo D; Bian Z; Su L; Liu K; Gu X; Guo X; Wang L; Zhang H; Tao K; Xing J
    Cancer Sci; 2021 Nov; 112(11):4772-4784. PubMed ID: 34490703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
    Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
    EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.
    Szymanski JJ; Sundby RT; Jones PA; Srihari D; Earland N; Harris PK; Feng W; Qaium F; Lei H; Roberts D; Landeau M; Bell J; Huang Y; Hoffman L; Spencer M; Spraker MB; Ding L; Widemann BC; Shern JF; Hirbe AC; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003734. PubMed ID: 34464388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
    Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
    Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy number variation in plasma as a tool for lung cancer prediction using Extreme Gradient Boosting (XGBoost) classifier.
    Yu D; Liu Z; Su C; Han Y; Duan X; Zhang R; Liu X; Yang Y; Xu S
    Thorac Cancer; 2020 Jan; 11(1):95-102. PubMed ID: 31694073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible.
    Jensen TJ; Goodman AM; Ellison CK; Holden KA; Kato S; Kim L; Daniels GA; Fitzgerald K; McCarthy E; Nakashe P; Mazloom AR; Almasri E; McLennan G; Grosu DS; Eisenberg M; Kurzrock R
    Mol Cancer Ther; 2021 Nov; 20(11):2274-2279. PubMed ID: 34465593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation.
    Zheng M; Hu Y; Gou R; Nie X; Li X; Liu J; Lin B
    Biomed Pharmacother; 2020 Apr; 124():109810. PubMed ID: 32000042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
    Balla A; Bhak J; Biró O
    Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
    Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
    Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic and survival impact of BCL9 and RPS6KB1 copy number variation detected from circulating free DNA in hepatocellular carcinoma.
    Youssef SS; El-Araby RE; Abbas EAE; Hassany M; Elbaz T
    Expert Rev Mol Diagn; 2023 Mar; 23(3):267-278. PubMed ID: 36803362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
    Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
    Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
    Chen X; Chang CW; Spoerke JM; Yoh KE; Kapoor V; Baudo C; Aimi J; Yu M; Liang-Chu MMY; Suttmann R; Huw LY; Gendreau S; Cummings C; Lackner MR
    Clin Cancer Res; 2019 Apr; 25(7):2254-2263. PubMed ID: 30617129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
    Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
    Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
    Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
    Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.
    Gao Y; Zhou N; Liu J
    Cancer Control; 2024; 31():10732748241255548. PubMed ID: 38764160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
    Jang H; Choi CM; Lee SH; Lee S; Jeong MK
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.